These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35018534)

  • 21. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV; Shah ED
    Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in pharmacological treatment of irritable bowel syndrome.
    Lazaraki G; Chatzimavroudis G; Katsinelos P
    World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).
    Smalley W; Falck-Ytter C; Carrasco-Labra A; Wani S; Lytvyn L; Falck-Ytter Y
    Gastroenterology; 2019 Sep; 157(3):851-854. PubMed ID: 31302098
    [No Abstract]   [Full Text] [Related]  

  • 24. Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
    Kasir R; Zakko S; Zakko P; Adler M; Lee A; Dhingra S; Guttermuth C
    Dig Dis Sci; 2016 Mar; 61(3):846-51. PubMed ID: 26362282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End points in irritable bowel syndrome.
    Mangel AW; Fehnel SE
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract]   [Full Text] [Related]  

  • 26. Undiagnosed Exocrine Pancreatic Insufficiency in Diarrhea-Predominant Irritable Bowel Syndrome.
    Lee AA; McNabb-Baltar J
    Dig Dis Sci; 2022 Dec; 67(12):5364-5365. PubMed ID: 35705731
    [No Abstract]   [Full Text] [Related]  

  • 27. Eluxadoline approved for irritable bowel syndrome with diarrhea.
    Traynor K
    Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
    [No Abstract]   [Full Text] [Related]  

  • 28. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
    Grover M; Camilleri M
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):960-2. PubMed ID: 24393804
    [No Abstract]   [Full Text] [Related]  

  • 31. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Bertrand J; Ghouzali I; Guérin C; Bôle-Feysot C; Gouteux M; Déchelotte P; Ducrotté P; Coëffier M
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1170-1176. PubMed ID: 25972430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical efficacy of Actimel for patients with the irritated bowel syndrome with prevailing diarrhea].
    Parfenov AI; Ruchkina IN; Tsaregorodtsev TM; Serova TI
    Eksp Klin Gastroenterol; 2005; (5):45-52. PubMed ID: 16518915
    [No Abstract]   [Full Text] [Related]  

  • 33. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome.
    Zhou Q; Zhang B; Verne GN
    Pain; 2009 Nov; 146(1-2):41-6. PubMed ID: 19595511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D): Patient Summary.
    American Gastroenterological Association
    Gastroenterology; 2019 Sep; 157(3):856-857. PubMed ID: 31378676
    [No Abstract]   [Full Text] [Related]  

  • 35. Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):109-11. PubMed ID: 26218792
    [No Abstract]   [Full Text] [Related]  

  • 36. Emerging drug for diarrhea predominant irritable bowel syndrome.
    Deiana S; Gabbani T; Bagnoli S; Annese V
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):247-61. PubMed ID: 25732091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): results from two separate surveys of HCPs and patients with IBS-D.
    Emmanuel A; Goosey RW; Wiseman G; Baker S; Törnblom H
    BMC Gastroenterol; 2020 Apr; 20(1):127. PubMed ID: 32336287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E; Kim S; Chong K; Lembo A; Pimentel M
    Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.